Evidence map›Paper›PMID 36644451›Full record

ReviewThe World Allergy Organization journal2023

Omalizumab may protect allergic patients against COVID-19: A systematic review.

Daniele Giovanni Ghiglioni, Et Laura Cozzi, Riccardo Castagnoli, Gaia Bruschi, Laura Maffeis, Paola Giovanna Marchisio, Gian Luigi Marseglia, Amelia Licari

Erratum issuedOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The World Allergy Organization journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Review
  3. Observational
  4. Bronchial Asthma and COVID-19: Etiology, Pathological Triggers, and Therapeutic Considerations.Pathophysiology : the official journal of the International Society for Pathophysiology · 2024
    Review
  5. Article
  6. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Daniele Giovanni GhiglioniFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, SC Pediatria Pneumoinfettivologia, Milan, Italy.
Et Laura CozziUniversity of Milan, Milan, Italy.
Riccardo CastagnoliPediatric Clinic, Department of Pediatrics, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.
Gaia BruschiUniversity of Milan, Milan, Italy.
Laura MaffeisFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, SC Pediatria Immunoinfettivologia, Milan, Italy.
Paola Giovanna MarchisioFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, SC Pediatria Pneumoinfettivologia, Milan, Italy.
Gian Luigi MarsegliaPediatric Clinic, Department of Pediatrics, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.
Amelia LicariPediatric Clinic, Department of Pediatrics, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · ITUniversity of Milan · ITUniversity of Pavia · ITNemours Children’s Clinic · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Omalizumab

Indexed as

COVID-19IFN-AlphaInterferonOmalizumabSARS-CoV-2

Identifiers

PMID36644451
PMCPMC9826982
OpenAlexW4313825804

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.